Biograil has secured $22.4 million in new funding to advance development of its BIONDD oral drug delivery platform, which is designed to administer therapeutics typically given by injection. The Copenhagen-based biotechnology company stated that the financing was backed by existing investors Verve Ventures and Megatrend Invest, with participation from High-Tech Gründerfonds (HTGF) through its HTGF Opportunity growth fund. HTGF initially joined Biograil’s seed investor group in 2019. Verve Ventures led the first close of a $9.5 million financing round announced in July 2025.
HTGF’s continued investment reflects its confidence in the company’s approach as it moves toward clinical development. Biograil’s BIONDD platform aims to enable the oral administration of certain biologic and other injectable medicines. The technology is housed in a standard-size capsule that dissolves in the stomach, releasing a device that attaches to the stomach wall and delivers the drug into surrounding tissue for systemic absorption.
The funding will support preparations for first-in-human testing, including nonclinical Good Laboratory Practice (GLP) studies and establishment of a Good Manufacturing Practice (GMP) manufacturing process. Biograil is targeting these milestones ahead of a larger financing round planned for 2027.
Source: drug-dev.com · Image: SDI, Samarra – Dec 21, 2019 11 by قناة التغيير, CC BY 3.0, via Wikimedia Commons
Get started today with Solo access →
